Targeting Barriers of Systems of Care in a Growing Multi-disciplinary Field
Purpose of Review
Cardio-oncology is a growing multi-disciplinary field that focuses on treating and preventing cardiovascular complications in cancer survivors and patients. This review summarizes the current clinical needs and system-based approaches to target barriers of care.
The field of cardio-oncology has experienced significant growth in recent years, and an increasing number of programs have been developed across the nation to provide improved and multi-disciplinary care to this patient population. Despite this burgeoning growth, practitioners in the field continue to face important challenges which include lack of administrative and departmental support, funding limitations, and gaps in the areas of mentoring, education, and research.
Despite continued growth, cardio-oncology providers continue to face a multitude of challenges. Early inclusion of multi-disciplinary stakeholders, oncologists, cardiovascular team members, and administrative leadership provides an opportunity to collaborate and achieve unique patient care and health system benefits, such as prevention of adverse cardiovascular outcomes, and facilitates the delivery of optimal oncologic treatment.
KeywordsCardio-oncology Cardiovascular disease Oncology Chemotherapy Radiation therapy Targeted therapy
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.• Fradley MG, Brown AC, Shields B, Viganego F, Damrongwatanasuk R, Patel AA, et al. Developing a comprehensive cardio-oncology program at a cancer institute: the Moffitt Cancer Center Experience. Oncol Rev. 2017;11(2):340 This article details the experience of developing a cardio-oncology program and provides an overview of the challenges faced and practical solution suggestions. CrossRefGoogle Scholar
- 4.American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2016–2017. Atlanta: American Cancer Society; 2016.Google Scholar
- 5.• Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, et al. Cardio-oncology services: rationale, organization, and implementation. A report from the ESC Cardio-Oncology council. Eur Heart J. 2018;2018:ehy453 A comprehensive review article by the European Society of Cardiology Cardio-Oncology Council that discusses the rationale, organization, and implementation of cardio-oncology services. Google Scholar
- 8.Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol : official journal of the American Society of Clinical Oncology. 2017;35(8):893–911.CrossRefGoogle Scholar
- 9.Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.CrossRefGoogle Scholar
- 10.Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–93.CrossRefGoogle Scholar
- 14.Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol : official journal of the American Society of Clinical Oncology. 2006;24(25):4107–15.CrossRefGoogle Scholar
- 18.Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–80.CrossRefGoogle Scholar
- 23.American College of Cardiology. Advancing the Cardiovascular Care of the Oncology Patient [Available from: https://www.acc.org/education-and-meetings/meetings/meeting-items/2018/06/06/06/54/2019-cardio-oncology. Accessed 10 Dec 2018.
- 24.United States Food and Drug Administration. FDA Public Workshop: cardiovascular toxicity assessment in oncology trials [Available from: https://www.fda.gov/drugs/newsevents/ucm513031.htm. Accessed 10 Dec 2018.
- 25.United States Food and Drug Administration. FDA Public Workshop: assessment of cardiovascular toxicities in immuno-oncology trials [Available from: https://www.fda.gov/Drugs/NewsEvents/ucm574741.htm. Accessed 10 Dec 2018.
- 26.NIH. Department of Health and Human Services [Available from: https://grants.nih.gov/grants/guide/pa-files/pa-16-035.html. Accessed 10 Dec 2018.